10x Genomics Statistics

Total Valuation

10x Genomics has a market cap or net worth of $4.67 billion. The enterprise value is $4.21 billion.

Market Cap	4.67B
Enterprise Value	4.21B

Important Dates

The next estimated earnings date is Thursday, August 6, 2026, after market close.

Earnings Date	Aug 6, 2026
Ex-Dividend Date	n/a

Share Statistics

10x Genomics has 126.96 million shares outstanding. The number of shares has increased by 4.06% in one year.

Current Share Class	116.88M
Shares Outstanding	126.96M
Shares Change (YoY)	+4.06%
Shares Change (QoQ)	+0.95%
Owned by Insiders (%)	8.06%
Owned by Institutions (%)	96.63%
Float	114.79M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	7.30
Forward PS	7.48
PB Ratio	5.82
P/TBV Ratio	6.22
P/FCF Ratio	38.19
P/OCF Ratio	36.50
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	6.59
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	34.43

Financial Position

The company has a current ratio of 5.90, with a Debt / Equity ratio of 0.10.

Current Ratio	5.90
Quick Ratio	5.25
Debt / Equity	0.10
Debt / EBITDA	n/a
Debt / FCF	0.67
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -2.98% and return on invested capital (ROIC) is -5.11%.

Return on Equity (ROE)	-2.98%
Return on Assets (ROA)	-4.48%
Return on Invested Capital (ROIC)	-5.11%
Return on Capital Employed (ROCE)	-7.63%
Weighted Average Cost of Capital (WACC)	15.60%
Revenue Per Employee	$542,261
Profits Per Employee	-$19,233
Employee Count	1,178
Asset Turnover	0.67
Inventory Turnover	3.02

Taxes

In the past 12 months, 10x Genomics has paid $3.41 million in taxes.

Income Tax	3.41M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +215.18% in the last 52 weeks. The beta is 2.11, so 10x Genomics's price volatility has been higher than the market average.

Beta (5Y)	2.11
52-Week Price Change	+215.18%
50-Day Moving Average	26.36
200-Day Moving Average	19.62
Relative Strength Index (RSI)	68.94
Average Volume (20 Days)	3,632,427

Short Selling Information

The latest short interest is 22.10 million, so 17.41% of the outstanding shares have been sold short.

Short Interest	22.10M
Short Previous Month	16.49M
Short % of Shares Out	17.41%
Short % of Float	19.26%
Short Ratio (days to cover)	6.94

Income Statement

In the last 12 months, 10x Genomics had revenue of $638.78 million and -$22.66 million in losses. Loss per share was -$0.18.

Revenue	638.78M
Gross Profit	445.11M
Operating Income	-68.80M
Pretax Income	-19.25M
Net Income	-22.66M
EBITDA	-30.67M
EBIT	-68.80M
Loss Per Share	-$0.18

Full Income Statement

Balance Sheet

The company has $539.85 million in cash and $81.39 million in debt, giving a net cash position of $458.46 million or $3.61 per share.

Cash & Cash Equivalents	539.85M
Total Debt	81.39M
Net Cash	458.46M
Net Cash Per Share	$3.61
Equity (Book Value)	814.32M
Book Value Per Share	6.31
Working Capital	556.14M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was $127.82 million and capital expenditures -$5.64 million, giving a free cash flow of $122.18 million.

Operating Cash Flow	127.82M
Capital Expenditures	-5.64M
Depreciation & Amortization	38.13M
Net Borrowing	n/a
Free Cash Flow	122.18M
FCF Per Share	$0.96

Full Cash Flow Statement

Margins

Gross margin is 69.68%, with operating and profit margins of -10.77% and -3.55%.

Gross Margin	69.68%
Operating Margin	-10.77%
Pretax Margin	-3.01%
Profit Margin	-3.55%
EBITDA Margin	-4.80%
EBIT Margin	-10.77%
FCF Margin	19.13%

Dividends & Yields

10x Genomics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4.06%
Shareholder Yield	-4.06%
Earnings Yield	-0.49%
FCF Yield	2.62%

Analyst Forecast

The average price target for 10x Genomics is $27.62, which is -24.84% lower than the current price. The consensus rating is "Buy".

Price Target	$27.62
Price Target Difference	-24.84%
Analyst Consensus	Buy
Analyst Count	16
Revenue Growth Forecast (3Y)	4.02%
EPS Growth Forecast (3Y)	26.64%

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

10x Genomics has an Altman Z-Score of 4.3 and a Piotroski F-Score of 4.

Altman Z-Score	4.3
Piotroski F-Score	4